FDA Approves Skinvive by Juvéderm: A Breakthrough in Neck Aesthetic Treatments

Understanding Skinvive by Juvéderm

FDA has officially approved Skinvive by Juvéderm, a revolutionary hyaluronic acid injectable treatment aimed at improving neck appearance by targeting neck lines specifically in adults over 21. Unlike traditional fillers which focus on adding volume, Skinvive is designed to retain the skin's natural moisture and enhance smoothness.

How Skinvive Works

Skinvive is applied with an ultrafine needle or cannula, ensuring a minimally invasive process with little to no downtime. Enriched with a small dosage of lidocaine, it promotes patient comfort during administration. With results lasting up to six months, treatments may be complemented by an optional touch-up after one month.

Clinical Study Insights

The recent FDA approval stemmed from a pivotal randomized, multicenter study demonstrating that 74.8% of patients experienced significant improvement in neck lines after a month. This effective solution addresses a notable gap in the lower face and neck treatments, establishing Skinvive as a preferred option.

Safety Profile of Skinvive

• Minor side effects like redness and swelling were observed.
• Most adverse events were mild and resolved swiftly.
• The FDA mandates training for providers before administering Skinvive.

This pioneering treatment reflects Allergan Aesthetics' dedication to meeting essential aesthetic needs and expanding their treatment portfolio in neck and lower face care.